Literature DB >> 23407908

Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis.

Yu-Yu Lu1, Jin-Hua Chen, Chun-Ru Chien, William Tzu-Liang Chen, Shih-Chuan Tsai, Wan-Yu Lin, Chia-Hung Kao.   

Abstract

AIM: The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to assess the diagnostic performance of FDG-PET or PET/CT in the detection of recurrent colorectal cancer (CRC) rising in patients with elevated CEA.
MATERIALS AND METHODS: The authors conducted a systematic MEDLINE search of published articles. Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity and specificity and positive and negative likelihood ratios, and summary receiver-operating characteristic curves in the detection of recurrent CRC in patients with elevated CEA.
RESULTS: Eleven studies with a total of 510 patients met the inclusion criteria. One hundred and six patients (106/510 = 20.8%) had true-negative FDG-PET (PET/CT) results in detection of recurrent CRC when rising CEA. The pooled estimates of sensitivity and specificity and positive and negative likelihood ratios of FDG-PET in the detection of tumor recurrence in CRC patients with elevated CEA were 90.3% (95% CI, 85.5-94.0%), 80.0% (95% CI, 67.0-89.6%), 2.88 (95% CI, 1.37-6.07), and 0.12 (95% CI, 0.07-0.20), respectively. The pooled estimates of sensitivity and specificity and positive and negative likelihood ratios of FDG-PET/CT in the detection of tumor recurrence in CRC patients with elevated CEA were 94.1% (95% CI, 89.4-97.1%), 77.2% (95% CI, 66.4-85.9%), 4.70 (95% CI, 0.82-12.13), and 0.06 (95% CI, 0.03-0.13), respectively.
CONCLUSIONS: Whole-body FDG-PET and PET/CT are valuable imaging tools for the assessment of patients with suspected CRC tumor recurrence based on the increase of CEA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23407908     DOI: 10.1007/s00384-013-1659-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  36 in total

1.  The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.

Authors:  Yasemin Sanli; Serkan Kuyumcu; Zeynep Gozde Ozkan; Leyla Kilic; Emre Balik; Cuneyt Turkmen; Duygu Has; Goknur Isik; Oktar Asoglu; Yersu Kapran; Isik Adalet
Journal:  Ann Nucl Med       Date:  2012-05-30       Impact factor: 2.668

2.  Intensive surveillance after stage II or III colorectal cancer: is it worth it?

Authors:  Richard M Goldberg
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

3.  Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.

Authors:  Yeh-You Shen; Ji-An Liang; Yen-Kung Chen; Chun-Yueh Tsai; Chia-Hung Kao
Journal:  Hepatogastroenterology       Date:  2006 May-Jun

4.  (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer.

Authors:  Long-Bang Chen; Jin-Long Tong; Hai-Zhu Song; Hong Zhu; Yu-Cai Wang
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

5.  Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels.

Authors:  Feng-Yuan Liu; Jinn-Shiun Chen; Chung-Rong Changchien; Chien-Yuh Yeh; Shu-Hsing Liu; Kung-Chu Ho; Tzu-Chen Yen
Journal:  Dis Colon Rectum       Date:  2005-10       Impact factor: 4.585

6.  Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.

Authors:  L E Moses; D Shapiro; B Littenberg
Journal:  Stat Med       Date:  1993-07-30       Impact factor: 2.373

7.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.

Authors:  P Flamen; S Stroobants; E Van Cutsem; P Dupont; G Bormans; N De Vadder; F Penninckx; L Van Hoe; L Mortelmans
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Should carcinoembryonic antigen be used in the management of patients with colorectal cancer?

Authors:  L A Carriquiry; A Piñeyro
Journal:  Dis Colon Rectum       Date:  1999-07       Impact factor: 4.585

9.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.

Authors:  F L Flanagan; F Dehdashti; O A Ogunbiyi; I J Kodner; B A Siegel
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

Review 10.  Role of carcinoembryonic antigen in the management of advanced colorectal cancer.

Authors:  E P Mitchell
Journal:  Semin Oncol       Date:  1998-10       Impact factor: 4.929

View more
  20 in total

Review 1.  Recent developments in colorectal imaging.

Authors:  Perry J Pickhardt
Journal:  Curr Opin Gastroenterol       Date:  2015-01       Impact factor: 3.287

Review 2.  [Importance of FDG-PET/computed tomography in colorectal cancer].

Authors:  S Kleiner; W Weber
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

3.  Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection.

Authors:  Agostino Chiaravalloti; Alessandro Fiorentini; Erika Palombo; Davide Rinino; Annamaria Lacanfora; Roberta Danieli; Carmen Di Russo; Daniele Di Biagio; Ettore Squillaci; Orazio Schillaci
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

4.  Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM.

Authors:  R Vera; E González-Flores; C Rubio; J Urbano; M Valero Camps; J J Ciampi-Dopazo; J Orcajo Rincón; V Morillo Macías; M A Gomez Braco; G Suarez-Artacho
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

5.  Clinical impact of PET/MR in treated colorectal cancer patients.

Authors:  Barbara J Amorim; Theodore S Hong; Lawrence S Blaszkowsky; Cristina R Ferrone; David L Berger; Liliana G Bordeianou; Rocco Ricciardi; Jeffrey W Clark; David P Ryan; Jennifer Y Wo; Motaz Qadan; Mark Vangel; Lale Umutlu; David Groshar; Lina G Cañamaques; Debra A Gervais; Umar Mahmood; Bruce R Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-29       Impact factor: 9.236

6.  The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.

Authors:  Wenfeng Li; Weiwei Yin; Rongying Ou; Ting Chen; Lingling Xiong; Dezhi Cheng; Deyao Xie; Xiangwu Zheng; Yunsheng Xu; Liang Zhao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

7.  F-18 FDG PET/CT in the assessment of patients with unexplained CEA rise after surgical curative resection for colorectal cancer.

Authors:  S Giacomobono; R Gallicchio; D Capacchione; A Nardelli; D Gattozzi; G Lettini; L Molinari; P Mainenti; A Cammarota; G Storto
Journal:  Int J Colorectal Dis       Date:  2013-07-12       Impact factor: 2.571

Review 8.  [Importance of FDG-PET/CT for surgery of rectal cancer].

Authors:  A Wiegering; K Herrmann; C Bluemel; A K Buck; C-T Germer
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

Review 9.  Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.

Authors:  Vetri Sudar Jayaprakasam; Viktoriya Paroder; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2021-05-06       Impact factor: 4.802

10.  Appropriateness criteria of FDG PET/CT in oncology.

Authors:  Archi Agrawal; Venkatesh Rangarajan
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.